Therapeutic targeting inflammation linking periodontitis and atherosclerotic comorbidities using cell-free DNA-capturing nanomaterials

This study demonstrates that polyamidoamine dendrimer-functionalized nanomaterials can therapeutically target periodontitis and atherosclerotic comorbidities by capturing cell-free DNA to inhibit inflammatory macrophage transformation and alleviate systemic inflammation.

The Gist

The Big Picture: Two Fires, One Spark

Imagine your body is a house.

• Periodontitis is a small, smoldering fire in the kitchen (your gums). It's a local infection that causes your teeth to loosen and your jawbone to rot.
• Atherosclerosis is a dangerous clog in the main water pipes (your arteries) that leads to heart attacks and strokes.

For a long time, doctors knew these two fires were often found in the same house. If you had gum disease, you were more likely to have heart disease. But they didn't know how the kitchen fire was setting the pipes on fire.

The Discovery: This paper found the "messenger" carrying the fire from the kitchen to the pipes. That messenger is Cell-Free DNA (cfDNA).

Think of cfDNA as ash and embers flying out of the kitchen fire. When your gums are inflamed, they release tiny pieces of DNA into your bloodstream. These floating DNA pieces act like a signal flare, telling your immune system, "Hey, there's an intruder! Attack!" This causes your immune system to go into overdrive, clogging your arteries with fatty gunk (plaque) and making the gum disease worse.

The Solution: The "DNA Vacuum"

The researchers asked: What if we could vacuum up these flying embers before they reach the pipes?

They invented a special nanomaterial (a tiny, microscopic sponge) called PG3@MSNs.

• The Sponge: It's made of silica (like glass) but coated with a special "sticky" polymer (PG3).
• The Magnet: Because DNA is negatively charged (like a magnet's south pole), the researchers made their nanomaterial positively charged (like a north pole).
• The Action: When injected into the body, these nanomaterials act like a super-magnet for DNA. They hunt down the floating DNA embers, grab them, and neutralize them.

What They Did (The Experiments)

The team tested this on mice that had both gum disease and clogged arteries. They tried two approaches:

1. The Systemic Approach (Vacuuming the whole house): They injected the nanomaterials into the mice's bellies. The nanomaterials traveled through the blood, caught the DNA, and stopped the inflammation.
   • Result: The gum disease got better, and the artery clogs shrank.
2. The Local Approach (Vacuuming the kitchen): They injected the nanomaterials directly into the gums.
   • Result: This stopped the embers from leaving the kitchen in the first place. The gum disease improved, and surprisingly, the artery clogs also got better because fewer embers were flying around.

The Catch: They tried the reverse, too. They tried to fix the arteries first and then treat the gums. It didn't work as well. This taught them that you must stop the local fire (gums) early to prevent the systemic disaster (heart disease). Once the whole house is on fire, it's much harder to put out.

How It Works Inside the Cells (The "Fat Cell" Metaphor)

Inside your blood vessels, there are immune cells called macrophages. Think of them as the body's garbage collectors.

• Normally, they eat up bad cholesterol.
• But when they are bombarded by the "DNA embers" (cfDNA), they get confused and angry. They turn into "Foam Cells"—bloated, angry garbage collectors filled with fat and inflammation. These foam cells are the main building blocks of heart attacks.

The nanomaterials stop the DNA embers from hitting the garbage collectors. Without the angry signal, the collectors stay calm, don't turn into foam cells, and the arteries stay clear.

The "Secret Agents" (Spp1 and Fabp4)

The researchers found that the DNA signal specifically wakes up two "bad agents" inside the cells: Spp1 and Fabp4.

• These agents are like the foremen telling the garbage collectors to pack on the fat and stop cleaning.
• The nanomaterials silence these agents, allowing the cells to return to normal.

The Takeaway

This study is a "proof of concept." It shows that:

1. Gum disease and heart disease are linked by floating DNA.
2. We can catch this DNA using smart, tiny nanomaterials.
3. Treating the gums (or catching the DNA) can actually save the heart.

It's like realizing that cleaning the kitchen (gums) isn't just about a clean house; it's about preventing the whole building from burning down. And now, we have a high-tech vacuum cleaner to help us do it.

Technical Summary

1. Problem Statement

Periodontitis (a local inflammatory disease of the gums) and atherosclerosis (a systemic inflammatory condition of the arteries) are strongly linked, with periodontitis acting as an independent risk factor for cardiovascular disease. However, the causal mechanism driving this local-systemic crosstalk remains unclear.

• The Gap: While it is known that periodontitis increases systemic inflammation, the specific molecular messenger facilitating this link has not been definitively targeted therapeutically.
• The Hypothesis: The authors propose that cell-free DNA (cfDNA) released from damaged periodontal tissues enters the circulation, activates Toll-like receptor 9 (TLR9), and drives a pro-inflammatory response that exacerbates atherosclerosis.
• The Challenge: Developing a therapeutic strategy that can simultaneously treat the local periodontal disease and the systemic atherosclerotic comorbidity by interrupting this specific signaling pathway.

2. Methodology

The study employed a multi-disciplinary approach combining clinical observation, nanomaterial engineering, in vivo animal modeling, and advanced omics analysis.

A. Clinical Correlation Study

• Cohort: 77 human subjects divided into three groups: Healthy, Periodontitis-only, and Periodontitis + Atherosclerosis.
• Analysis: Measured plasma cfDNA levels and correlated them with periodontal clinical parameters (probing depth, plaque index) and atherosclerosis severity (vessel stenosis, plaque area).

B. Nanomaterial Design and Characterization

• Material: Synthesized PG3@MSNs, consisting of mesoporous silica nanoparticles (MSNs) functionalized with third-generation polyamidoamine dendrimers (PG3).
• Mechanism: The cationic PG3 surface allows for high-affinity electrostatic binding to negatively charged cfDNA.
• Properties: The material is biodegradable (H2O2-responsive), has low cytotoxicity compared to free PG3, and exhibits high DNA binding capacity.

C. In Vivo Animal Models

• Model: ApoE-/- mice fed a Western diet (to induce atherosclerosis) with ligature-induced periodontitis.
• Experimental Groups:
  1. Systemic Treatment: Intraperitoneal injection of PG3@MSNs.
  2. Local Treatment: Local injection of PG3@MSNs into periodontal tissues.
  3. Control Groups: Ligature + PBS, Ligature-free controls.
• Biodistribution: Used FITC-labeled CpG DNA (injected locally) and Cy7-labeled PG3@MSNs (systemically injected) to track cfDNA capture in major organs via IVIS imaging.

D. Molecular and Cellular Analysis

• Transcriptomics: Bulk RNA sequencing of macrophages (RAW 264.7) treated with oxLDL and CpG DNA.
• Single-Cell RNA Sequencing (scRNA-seq): Analyzed macrophage heterogeneity and differentiation trajectories (pseudotime analysis) to identify specific subpopulations.
• Immunofluorescence/IHC: Validated protein expression of TLR9, inflammatory markers (TNF-α, CXCL2), and foam cell markers (SPP1, FABP4) in aortic and periodontal tissues.

3. Key Contributions

1. Identification of cfDNA as the Causal Link: Provided clinical and experimental evidence that periodontitis-derived cfDNA circulates systemically and directly correlates with periodontal severity, acting as a driver for atherosclerosis progression via the TLR9 pathway.
2. Development of a Dual-Action Nanoplatform: Engineered PG3@MSNs that act as "molecular sponges" to capture cfDNA, effectively decoupling the local inflammation from the systemic response.
3. Mechanistic Insight into Foam Cell Formation: Discovered that cfDNA-TLR9 signaling drives the transformation of macrophages into inflammatory foam cells by upregulating specific lipid-related markers (Spp1 and Fabp4).
4. Proof of Concept for Holistic Therapy: Demonstrated that capturing cfDNA (either locally or systemically) can simultaneously alleviate alveolar bone loss (periodontitis) and arterial plaque formation (atherosclerosis).

4. Key Results

Clinical Findings

• Plasma cfDNA levels were significantly elevated in patients with periodontitis and were highest in those with both periodontitis and atherosclerosis.
• Correlation: cfDNA levels strongly correlated with periodontal parameters (probing depth, plaque index) but showed no significant correlation with the severity of existing atherosclerosis (number of diseased vessels). This suggests cfDNA is a driver of the onset/progression rather than a marker of established plaque burden.

Nanomaterial Performance

• Binding: PG3@MSNs effectively bound DNA in vitro and inhibited TLR9 activation (reducing TNF-α and IL-6 secretion).
• Biodistribution: Systemically administered PG3@MSNs successfully co-localized with periodontally injected DNA in major organs (heart, liver, spleen, lung, kidney), confirming the capture of periodontal cfDNA in circulation.

Therapeutic Efficacy in Mice

• Systemic Administration: Reduced plasma cfDNA, total cholesterol (TC), triglycerides (TG), and inflammatory cytokines. Significantly reduced alveolar bone loss and aortic plaque size. Improved plaque stability (increased collagen content).
• Local Administration: Local injection of PG3@MSNs into the periodontium also reduced systemic cfDNA levels and alleviated both periodontal bone loss and atherosclerotic plaque formation.
• Timing: Early intervention (before severe systemic inflammation is established) was highly effective. Once severe systemic inflammation was established, systemic intervention alone had limited efficacy on local periodontal damage, highlighting the importance of early local control.

Molecular Mechanism (scRNA-seq & Transcriptomics)

• Macrophage Subclusters: scRNA-seq identified three macrophage clusters:
  • Macro-1: Unchallenged.
  • Macro-2: Pro-inflammatory (high Tnf, Cxcl2).
  • Macro-3: Foamy/Inflammatory (high Fabp4, Spp1).
• Differentiation: Pseudotime analysis showed a trajectory from Macro-1 $\to$ Macro-2 $\to$ Macro-3. CpG DNA stimulation accelerated this transition.
• Intervention: PG3@MSNs treatment reversed the upregulation of Spp1 (Osteopontin) and Fabp4 (Fatty Acid-Binding Protein 4), preventing the formation of inflammatory foam cells and reducing lipid accumulation in macrophages.

5. Significance

• Paradigm Shift: This study moves beyond the correlation between periodontitis and heart disease to establish a causal mechanism mediated by cfDNA.
• Therapeutic Innovation: It introduces a novel "cfDNA-capturing" strategy using nanomaterials that offers a holistic treatment for local-systemic inflammatory comorbidities, rather than treating them as separate entities.
• Clinical Implication: The findings suggest that early detection and management of periodontitis (to prevent cfDNA spillover) or the use of cfDNA-scavenging therapies could be a viable strategy to prevent or slow the progression of atherosclerosis in high-risk patients.
• Target Validation: It validates Spp1 and Fabp4 as critical downstream targets of the cfDNA-TLR9 axis in macrophage foam cell formation, offering new targets for cardiovascular pharmacotherapy.

In summary, the paper provides a robust proof-of-concept that engineering nanomaterials to scavenge cell-free DNA can break the pathological loop between periodontitis and atherosclerosis, offering a promising avenue for treating complex inflammatory comorbidities.